NCT03607383

Brief Summary

Red yeast rice is a source of active compounds in reducing LDL levels with practically no side effects. Molval Fort is a natural product available in the Lebanese market with a combination of red yeast rice extracts, EPA/DHA and coenzyme Q10. The investigators are conducting this study to explore the effect of red yest rice extracts based product on LDL and its side effects in a sample of primary care Lebanese patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 7, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 31, 2018

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2020

Completed
Last Updated

October 8, 2019

Status Verified

October 1, 2019

Enrollment Period

2.2 years

First QC Date

June 26, 2018

Last Update Submit

October 4, 2019

Conditions

Keywords

statinsred rice yeastadverse effectscholesterol, LDLtreatment outcometolerability

Outcome Measures

Primary Outcomes (1)

  • LDL reduction

    after an eight week treatment, cholesterol LDL levels' reduction is compared in the two groups

    eight weeks

Secondary Outcomes (1)

  • incidence of side effects

    eight weeks

Other Outcomes (1)

  • physician and patient satisfaction

    eight weeks

Study Arms (2)

Red rice yeast group

EXPERIMENTAL

Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions

Drug: Red Rice Yeast Extract

Statin group

ACTIVE COMPARATOR

Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks

Drug: Statin

Interventions

adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks

Red rice yeast group
StatinDRUG

Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks

Statin group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient (\>18 years)
  • Indication to mild or moderate statin based on AHA 2013 guidelines
  • Treatment naïve

You may not qualify if:

  • Allergy to rice
  • Renal or hepatic terminal disease
  • Any contra indication to statin treatment
  • Pregnancy wish during study period
  • Familial hypercholesterolemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saint Anthony Primary Care Center

Jdeïdé, Lebanon

RECRUITING

MeSH Terms

Conditions

Dyslipidemias

Interventions

red yeast riceHydroxymethylglutaryl-CoA Reductase Inhibitors

Condition Hierarchy (Ancestors)

Lipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Anticholesteremic AgentsHypolipidemic AgentsAntimetabolitesMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesEnzyme InhibitorsLipid Regulating AgentsTherapeutic Uses

Study Officials

  • Marouan Zoghbi

    Hôtel Dieu de France Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2018

First Posted

July 31, 2018

Study Start

February 7, 2018

Primary Completion

April 30, 2020

Study Completion

April 30, 2020

Last Updated

October 8, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations